Laru-Zova Meets Pivotal X-Linked Retinitis Pigmentosa Endpoint
Beacon Therapeutics reported that the pivotal VISTA study met its FDA-endorsed Month 12 primary endpoint in 85 males with RPGR-associated X-linked retinitis pigmentosa. A gain of at least 15 low-luminance visual acuity letters occurred…
